Activity-based probe compounds, compositions, and methods of use

CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 62/438,959, filed December 23, 2016, the disclosure of which is incorporated herein by reference in its entirety.

STATEMENT OF GOVERNMENT SUPPORT This invention was made with government support under contract EB005011 awarded by the National Institutes of Health. The government has certain rights in this invention.

Currently, various technologies are being developed for use in the areas of molecular imaging and disease monitoring. Optical fluorescence imaging, in particular, is an approach that is beginning to show promise as a clinical tool, given its sensitivity, specificity, and non-invasiveness. The specificity of fluorescent optical probes can, in some cases, be provided by their biological targets. For example, optical probes recognized by enzyme targets in biological samples often generate highly specific signals if the probe's fluorescence is only released upon enzymatic reaction. Ideally, the fluorescent moiety of the probe remains bound to its enzyme target even after the fluorescent signal is activated by the enzymatic reaction. Such fluorescent activity-based probes (ABPs) have been described in the context of protease targets. Blum et al. (2009) PLoS One 4:e6374; doi:10.1371/journal.pone.0006374. ABPs can be distinguished from simple fluorogenic substrates by the permanent covalent bond resulting from the reaction of ABPs with catalytic residues in the active site of enzymes. While fluorescent substrates appear advantageous due to signal amplification resulting from catalytic turnover by their target enzymes, ABPs have been found to exhibit increased tissue uptake kinetics and prolonged retention of the probe in target tissues due to their covalent modification of the target enzyme.

Among the target enzymes of interest for use with fluorescence-based optical probes are proteases, particularly cysteine proteases. Cysteine cathepsins are a family of proteases that play important roles in health and disease. Reiser et al. (2010) J. Clin. Invest. 120:3421-31. Although their function has been primarily described as being limited to the endosomal pathway, accumulating evidence indicates that they are key regulators of matrix degradation, suggesting that they also function in extracellular contexts. Broemme and Wilson (2011) Role of Cysteine Cathepsins in Extracellular Proteolysis. Biology of Extracellular Matrix 2:23-51. Additionally, members of the cysteine cathepsin family have been shown to be key players in the development and progression of several types of cancer. Mohamed and Sloane (2006) Nat. Rev. Cancer (2006) 6:764-75; Palermo and Joyce (2008) Trends Pharmacol. Sci. 29:22-8. Furthermore, altered expression of cystatins, endogenous inhibitors of cathepsins, has been observed in cancer. Cox (2009) Cystatins and cancer. Front. Biosci. 14:463-74. These observations, combined with potential changes in the intracellular and extracellular milieu, emphasize the importance of tools that allow direct assessment of the activity of these proteases in the context of the native tumor microenvironment. Several ABPs targeting the cysteine cathepsin family have been synthesized. Edgington et al. (2011) Curr. Opin. Chem. Biol. 15:798-805. In particular, fluorescently quenched ABP (qABP) has proven to be a powerful tool for noninvasive optical imaging of cancer and subsequent histological characterization of target cathepsins at the cellular and protein levels. Blum et al. (2007) Nat. Chem. Biol. 3:668-77; Verdoes et al. (2012) Chem. Biol. 19:619-28.

Activity-based inhibitors of dipeptidyl peptidase I based on 2,3,5,6-tetrafluorophenoxyarylmethyl ketone reactive groups have been reported (Deu et al. (2010) Chem. Biol. 17:808-819), but these inhibitors were nonpeptidic and did not contain detectable groups.

Quenched activity-based peptidic inhibitors for use in fluorescent imaging of cells containing active proteases such as cathepsins have also been reported. See, for example, U.S. Patent Application Publication No. 2007/0036725. These probes utilize ester-linked acyloxymethylketone reactive groups to bind to the protease active site. In some cases, the activity-based fluorescent probes are non-peptidic. See, for example, PCT International Publication No. WO2012/118715. In some cases, activity-based probes are used to radiolabel their target enzymes. See, for example, PCT International Publication No. WO2009/124265.

Other activity-based inhibitors of caspases and other cysteine proteases are reported in PCT International Publication No. WO2012/021800; U.S. Patent Application Publication No. 2002/0052323; U.S. Patent Application Publication No. 2002/0028774; PCT International Publication No. WO96/41638; and European Patent Application Publication No. 0272671.

However, there remains a need in the art for novel activity-based fluorescent probes of cysteine proteases that have higher cellular uptake, target a broader range of cysteine protease activities, and provide high detection sensitivity and lower background signal.

<p><patcit num="1"><text>US Patent Application Publication No. 2007/0036725</text></patcit><patcit num="2"><text>International Publication No. 2012/118715</text></patcit><patcit num="3"><text>International Publication No. 2012/021800</text></patcit><patcit num="4"><text>US Patent Application Publication No. 2002/0052323</text></patcit><patcit num="5"><text>US Patent Application Publication No. 2002/0028774</text></patcit><patcit num="6"><text>International Publication No. 96/41638</text></patcit><patcit num="7"><text>European Patent Application Publication No. 0272671</text></patcit></p>

<p><nplcit><text>Blum et al. (2009) PLoS One 4:e6374; doi:10.1371/journal.pone.0006374</text></nplcit><nplcit><text>Reiser et al. (2010) J. Clin. Invest. 120:3421-31</text></nplcit><nplcit><text>Wilson (2011) Role of Cysteine Cathepsins in Extracellular Proteolysis. Biology of Extracellular Matrix vol. 2, pp. 23-51</text></nplcit><nplcit><text>Mohamed and Sloane (2006) Nat. Rev. Cancer (2006) 6:764-75; Palermo and Joyce (2008) Trends Pharmacol. Sci. 29:22-8</text></nplcit><nplcit><text>Cox (2009) Cystatins and cancer. Front. Biosci. 14:463-74</text></nplcit><nplcit><text>Edgington et al. (2011) Curr. Opin. Chem. Biol. 15:798-805</text></nplcit></p>

<p>SUMMARY OF THE INVENTION The present invention addresses these and other needs by providing compounds, compositions, and methods of using the compounds and compositions that target animal proteases.</p><p>In particular, according to one aspect of the present invention, a compound of structural formula (II): <img file="JP7720102B2_D0001.tif" /> wherein D comprises a benzoindole dye; L₁is the linker; AA₁is an amino acid side chain; U is O, NH, or S; R₁is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, or a protecting group, optionally substituted with 1 to 3 A groups; each A is independently alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, aryl, aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl, aralkamino, heteroaryl, heteroaryloxy, heteroarylamino, heteroaralkyl, heteroaralkoxy, heteroaralkanoyl L is aryl, heteroaralkamino, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkoxy, cycloalkanoyl, cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalkyl, heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino, hydroxyl, thio, amino, alkanoylamino, aroylamino, aralkanoylamino, alkylcarboxy, carbonate, carbamate, guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, sulfonyl, sulfonamido, or azido;₃is a linker and Q comprises a quencher.</p><p>In some embodiments, the benzoindole dye has the structure: <img file="JP7720102B2_D0002.tif" /> (wherein o is an integer of 1 to 4; R₂is C optionally substituted with sulfonate or carbonate₂~C₈is an alkyl group;₃are independently, C₁~C₆is an alkyl group; L₄is an optionally substituted alkyl linker, wherein each carbon atom is optionally replaced with a heteroatom.</p><p>In more specific embodiments, the benzoindole dye has the structure: <img file="JP7720102B2_D0003.tif" /> It has.</p><p>In some embodiments of the compound of Structural Formula (II), L₁is an optionally substituted alkyl linker, where each carbon atom is optionally replaced with a heteroatom or is AA₁is an aralkyl amino acid side chain optionally substituted with 1-3 A groups; U is O; or L₃is an optionally substituted alkyl linker, wherein each carbon atom is optionally replaced with a heteroatom, or L₃-Q is <img file="JP7720102B2_D0004.tif" /> wherein R comprises a QSY quencher or a QC-1 quencher; and n is an integer from 1 to 8. More specifically, the QSY quencher may be a hydrophilic QSY quencher or a sulfo-QSY quencher. In some embodiments, the QC-1 quencher has the structure: <img file="JP7720102B2_D0005.tif" /> It has.</p><p>In other embodiments, the compound of the present invention has formula (III): <img file="JP7720102B2_D0006.tif" /> wherein R comprises a QSY quencher or a QC-1 quencher; m and n are independently integers from 1 to 8; and R₁, A.A.₁and D is as defined above).</p><p>More specifically, in these compounds, R is <img file="JP7720102B2_D0007.tif" /> and D may be <img file="JP7720102B2_D0008.tif" /> It may be.</p><p>In an even more specific embodiment, the compound has the structure: <img file="JP7720102B2_D0009.tif" /> may have:</p><p>According to another aspect, the present invention provides a composition for use in labeling a protease in an animal, comprising a compound of the present disclosure and a pharmaceutically acceptable carrier.</p><p>According to another aspect, the present invention provides a method of labeling a protease in an animal, the method comprising administering to the animal a composition of the present disclosure.</p><p>The present invention still further provides a method for visualizing a tumor in an animal, comprising the steps of administering a composition of the present disclosure to the animal; and measuring in the animal a detectable signal generated from the reaction of the composition with a cathepsin cysteine protease, wherein the detectable signal is associated with a tumor in the animal.</p><p>In specific method embodiments, the detectable signal is a fluorescent signal. In other specific method embodiments, the fluorescent signal is generated in the vicinity of the tumor.</p><p>In an embodiment of the present invention, for example, the following items are provided:</p><p>(Item 1) Formula (II) <img file="JP7720102B2_D0010.tif" /> wherein D comprises a benzoindole dye; L₁is the linker; AA₁is an amino acid side chain; U is O, NH, or S; R₁is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, or a protecting group, optionally substituted with 1 to 3 A groups; each A is independently alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, aryl, aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl, aralkamino, heteroaryl, heteroaryloxy, heteroarylamino, heteroaralkyl, heteroaralkoxy, heteroaralkanoyl L is aryl, heteroaralkamino, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkoxy, cycloalkanoyl, cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalkyl, heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino, hydroxyl, thio, amino, alkanoylamino, aroylamino, aralkanoylamino, alkylcarboxy, carbonate, carbamate, guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, sulfonyl, sulfonamido, or azido;₃is a linker and Q comprises a quencher.</p><p>(Item 2) The benzoindole dye has the structure: <img file="JP7720102B2_D0011.tif" /> (wherein o is an integer of 1 to 4; R₂is C optionally substituted with sulfonate or carbonate₂~C₈is an alkyl group;₃are independently, C₁~C₆is an alkyl group; L₄is an optionally substituted alkyl linker, wherein each carbon atom is optionally replaced with a heteroatom.</p><p>(Item 3) The benzoindole dye has the structure: <img file="JP7720102B2_D0012.tif" /> Item 3. The compound according to item 2, having the formula:</p><p>(Item 4)L₁is an optionally substituted alkyl linker, wherein each carbon atom is optionally replaced with a heteroatom.</p><p>(Item 5)AA₁is an aralkyl amino acid side chain optionally substituted with 1 to 3 A groups.</p><p>(Item 6) The compound according to Item 1, wherein U is O.</p><p>(Item 7)L₃is an optionally substituted alkyl linker, and each carbon atom is optionally replaced with a heteroatom.</p><p>(Item 8)L₃-Q is <img file="JP7720102B2_D0013.tif" /> wherein R comprises a QSY quencher or a QC-1 quencher; and n is an integer of 1 to 8.</p><p>(Item 9) The compound according to item 8, wherein the QSY quencher is a hydrophilic QSY quencher. (Item 10) The compound according to item 9, wherein the hydrophilic QSY quencher is a sulfo-QSY quencher.</p><p>(Item 11) The QC-1 quencher has the structure: <img file="JP7720102B2_D0014.tif" /> Item 9. The compound according to item 8, having the formula:</p><p>(Item 12) Formula (III): <img file="JP7720102B2_D0015.tif" /> wherein R comprises a QSY quencher or a QC-1 quencher; and m and n are independently integers from 1 to 8.</p><p>(Item 13) R <img file="JP7720102B2_D0016.tif" /> and D is <img file="JP7720102B2_D0017.tif" /> Item 13. The compound according to item 12, wherein</p><p>(Item 14) Structure: <img file="JP7720102B2_D0018.tif" /> Item 14. The compound according to item 13, having the formula:</p><p>(Item 15) A composition for use in labeling a protease in an animal, comprising the compound according to any one of items 1 to 14 and a pharmaceutically acceptable carrier.</p><p>(Item 16) A method for labeling a protease in an animal, comprising administering the composition described in Item 15 to the animal.</p><p>(Item 17) A method for visualizing a tumor in an animal, comprising the steps of administering to the animal the composition described in Item 15; and measuring in the animal a detectable signal generated from the reaction of the composition with a cathepsin cysteine protease, wherein the detectable signal is associated with a tumor in the animal.</p><p>(Item 18) The method according to Item 17, wherein the detectable signal is a fluorescent signal.</p><p>(Item 19) The method described in Item 18, wherein the fluorescent signal occurs around the tumor.</p>

<figref num="1">Figure 1A shows the structure of qABP GB137(1) and probes 2-8. Figure 1B shows the labeling profile of probes 1-8 in live RAW cells at 1 μM. Figure 1C shows the concentration-dependent labeling by probes 1 and 8 in live RAW cells. Figure 1D shows the total cathepsin labeling intensity of probes 1-8 in live RAW cells relative to 5 μM GB137(1).</figref>

<figref num="2">Figure 2A shows concentration-dependent labeling of RAW cell lysates with probe 8 at pH 5.5. Figure 2B shows the time course of labeling with 0.5 μM probe 8 in live RAW cells. Figure 2C shows the inhibition of labeling of probes 1 and 8 in live RAW cells by pretreatment with JPM-OEt (50 μM) and serum stability. Figure 2D shows live-cell fluorescence microscopy of RAW cells exposed to 1 μM probe 8 (top row of panels) and colocalization with lysotracker (second row of panels, scale bar 10 μm).</figref>

<figref num="3-1">Figure 3A shows a time course of noninvasive optical imaging of tumor-bearing mice injected with probes 8 and 1 (right panel). The lower panel shows the optimal fluorescence contrast at each time point. Figure 3B shows time-dependent tumor-specific fluorescence (tumor minus background) for mice treated with probes 1 or 8 (n = 3; data represent mean ± standard error). Figure 3C shows ex vivo tumor fluorescence (upper panel) and in vivo fluorescently labeled proteins after SDS-PAGE visualized by in-gel fluorescent scanning (lower panel).</figref><figref num="3-2">Figure 3D shows the fluorescence intensity at the endpoints of noninvasive optical imaging (shown in 3A), ex vivo tumor imaging, and fluorescent labeling in gels (shown in 3C). The intensity is relative to probe 1 (n = 3; data represent mean ± standard error). Figure 3E shows fluorescence microscopy of a probe 8 (left panel)-treated tumor tissue section with CD68 immunostaining (middle panel) and nuclear staining (DAPIright panel, scale bar 50 μm). Figure 3F shows a 3D reconstruction of a probe 8 (red in the original)-treated tumor tissue section with CD68 immunostaining (green in the original) and nuclear staining (DAPIblue in the original).</figref>

<figref num="4">Figure 4A shows immunoprecipitation of BMV109 (probe 8)-labeled cysteine cathepsins. Figures 4B and 4C show concentration-dependent labeling of live RAW cells with probes 1 to 8. Panels 4B and 4C were each run on the same gel.</figref>

<figref num="5-1">Figure 5A shows noninvasive optical imaging of tumor-bearing mice 8 hours after injection of probes 1, 2, 6, or 8. The bottom panel shows the optimal fluorescence contrast at each time point. Figure 5B shows the time-dependent tumor-specific fluorescence (tumor minus background) for mice treated with probes 1, 2, 6, or 8 (n=3; data represent the mean ± standard error).</figref><figref num="5-2">Figure 5C shows ex vivo tumor fluorescence (upper panel) and in vivo fluorescently labeled proteins after SDS-PAGE visualized by in-gel fluorescent scanning (lower panel). Figure 5D shows the endpoint fluorescence intensity of noninvasive optical imaging (shown in 5A), ex vivo tumor imaging, and in-gel fluorescent labeling (shown in 5C). Intensity for probe 1 is shown (n=3; data represent mean ± standard error).</figref><figref num="5-3">Figure 5E shows fluorescence microscopy of probe 8 (first, third, and fourth columns)-treated tumor tissue sections with CD68 immunostaining (second, third, and fourth columns) and nuclear staining (DAPI - third and fourth columns, scale bar 50 μm). A no-probe control (middle row panel) and an isotype control for immunostaining (bottom row panel) are shown. Figure 5F shows colocalization of probe 8 (Cy5) and CD68 (FITC).</figref>

<figref num="6">Figure 6A shows a comparison of in vivo and ex vivo data for BMV109-DyLight780 and BMV109-ICG (10 nmol, 24 h, Pearl, ex/em = 785/820 nm). Figure 6B shows an ex vivo study of various concentrations of BMV109-Dylight780 and BMV109-ICG (10 nmol, 50 nmol, 100 nmol, 24 h, Pearl, ex/em = 785/820 nm).</figref>

Cysteine cathepsins are a family of proteases that play important roles in both normal cellular physiology and the pathology of many human diseases. Accordingly, several substrate and activity-based probe (ABP) classes have been developed to study the function of these enzymes. Provided herein, in some embodiments, is a class of quenched fluorescent activity-based probes containing phenoxymethyl ketone (PMK) electrophiles. These reagents exhibit enhanced and broad reactivity toward cysteine cathepsins, resulting in dramatically improved in vitro and in vivo labeling properties compared to previously reported ABPs. Furthermore, the probes are demonstrated herein to highlight tumors in mice with unprecedented signal intensity and contrast. These novel reagents enable the study of cysteine cathepsins at the organism, tissue, cell, and protein levels in diverse models of human disease. Examples of such reagents are described in PCT International Publication No. WO 2014/145257, which is incorporated herein by reference in its entirety.

compound

Thus, in some aspects, the present disclosure provides novel compounds for use in labeling protease enzymes, particularly cathepsins. The compounds of the present disclosure have the formula (I): <img file="JP7720102B2_D0019.tif" /> where L is an ether bond leaving element; T is a targeting element; and D is a detectable element.

The targeting element T of the compound may be a peptidic or non-peptidic structure, and preferably targets the compound to cysteine proteases.

For these purposes, non-limiting examples of non-peptidic structural elements usefully incorporated into the present compounds are described in PCT International Publication No. WO 2012/118715, which is incorporated herein by reference in its entirety. In a preferred embodiment, the non-peptidic targeting element comprises a triazole structure.

Specific examples of compounds of the invention having non-peptide targeting moieties are: <img file="JP7720102B2_D0020.tif" /> is.

Non-limiting examples of peptidic structural elements that can be usefully incorporated into the present compounds for targeting the compounds to cysteine proteases, particularly cysteine cathepsins, are described in PCT International Publication No. WO2009/124265, which is incorporated herein by reference in its entirety.

In some embodiments of the compound, DT- is <img file="JP7720102B2_D0021.tif" /> (In the formula, L₁is the linker; AA₁is an amino acid side chain; U is O, N, or S; R₁is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, or a protecting group, optionally substituted with 1 to 3 A groups; each A is independently alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, aryl, aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl, aralkamino, heteroaryl, heteroaryloxy, heteroarylamino, heteroaralkyl, heteroaralkoxy, heteroaralkanoyl , heteroaralkamino, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkoxy, cycloalkanoyl, cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalkyl, heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino, hydroxyl, thio, amino, alkanoylamino, aroylamino, aralkanoylamino, alkylcarboxy, carbonate, carbamate, guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, sulfonyl, sulfonamido, or azido).

As used herein, the term "alkyl" refers to the radical of a saturated aliphatic group, including a straight-chain alkyl group, a branched-chain alkyl group, a cycloalkyl (alicyclic) group, an alkyl-substituted cycloalkyl group, and a cycloalkyl-substituted alkyl group. In some embodiments, a straight-chain or branched-chain alkyl group may have a chain length greater than or equal to 1000 carbon atoms in its backbone (e.g., C for straight chain).₁~C₃₀, C for branched chains₃~C₃₀Likewise, some cycloalkyls have from 3-10 carbon atoms in their ring structure, and more specifically have 5, 6 or 7 carbons in the ring structure.

Furthermore, the term "alkyl" (or "lower alkyl"), as used throughout the specification, examples, and claims, is intended to include both "unsubstituted alkyl" and "substituted alkyl," the latter of which refers to an alkyl moiety having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, halo, hydroxyl, carbonyl (such as keto, carboxy, alkoxycarbonyl, formyl, or acyl), thiocarbonyl (such as thioester, thioacetate, or thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, thio, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aralkyl, or aromatic or heteroaromatic moieties. Those of skill in the art will understand that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. For example, the substituents of a substituted alkyl include substituted or unsubstituted amino, azido, imino, amido, phosphoryl (including phosphonates and phosphinates), sulfonyl (including sulfates, sulfonamides, sulfamoyl, and sulfonates), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), -CF₃, -CN, etc. Exemplary substituted alkyls are described below. Cycloalkyl can be substituted with alkyl, alkenyl, alkoxy, alkylthio, aminoalkyl, carbonyl-substituted alkyl, -CF₃, -CN, and the like.

As used herein, the term "alkoxy" refers to an alkyl group, and in certain particular embodiments, a lower alkyl group having an oxygen attached thereto. Representative alkoxy groups include methoxy, ethoxy, propoxy, t-butoxy, and the like.

As used herein, the term "alkenyl" refers to an aliphatic group containing at least one double bond and is intended to include both "unsubstituted alkenyl" and "substituted alkenyl," the latter of which refers to an alkenyl moiety having substituents replacing a hydrogen on one or more carbons of the alkenyl group. Such substituents may appear on one or more carbons that are either included or not included in one or more double bonds. Furthermore, such substituents include all of those contemplated for alkyl groups discussed above, except where stability would be impaired. For example, substitution of alkenyl groups with one or more alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl groups is contemplated.

When used with chemical moieties such as acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy, the term "C_x~y" is meant to include groups containing x to y carbons in the chain. For example, "C_x~yThe term "C-alkyl" refers to substituted or unsubstituted saturated hydrocarbon groups including straight-chain alkyl and branched-chain alkyl groups containing x to y carbon atoms in the chain, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl.₀-alkyl" denotes a hydrogen if the group is in a terminal position, or a bond if it is internal._2~y-alkenyl" and "C_2~yThe term "alkynyl" refers to substituted or unsubstituted unsaturated aliphatic groups similar in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.

As used herein, the term "alkylamino" refers to an amino group substituted with at least one alkyl group.

As used herein, the term "alkylthio" refers to a thiol group substituted with an alkyl group and may be represented by the general formula alkyl-S-.

As used herein, the term "alkynyl" refers to an aliphatic group containing at least one triple bond and is intended to include both "unsubstituted alkynyl" and "substituted alkynyl," the latter of which refers to an alkynyl moiety having substituents replacing a hydrogen on one or more carbons of the alkynyl group. Such substituents may appear on one or more carbons that are either included or not included in one or more triple bonds. Furthermore, such substituents include all of those contemplated for alkyl groups discussed above, except where stability would be impaired. For example, substitution of alkynyl groups with one or more alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl groups is contemplated.

As used herein, the term "amide" refers to a group <img file="JP7720102B2_D0022.tif" /> (In the formula, R^xand R^yeach independently represents hydrogen or a hydrocarbyl group, or R^xand R^ytogether with the N atom to which they are attached complete a heterocycle having 4 to 8 atoms in the ring structure).

The terms "amine" and "amino" are art-recognized and refer to both unsubstituted and substituted amines and their salts, e.g., <img file="JP7720102B2_D0023.tif" /> (In the formula, R^x, R^yand R^zeach independently represents hydrogen or a hydrocarbyl group, or R^xand R^yrefers to a moiety that can be represented by (which together with the N atom to which they are attached complete a heterocycle having 4 to 8 atoms in the ring structure).

As used herein, the term "aminoalkyl" refers to an alkyl group substituted with an amino group.

As used herein, the term "aralkyl" refers to an alkyl group substituted with an aryl group.

As used herein, the term "aryl" includes substituted or unsubstituted monocyclic aromatic groups in which each atom of the ring is carbon. In certain embodiments, the ring is 5- to 7-membered, and in more specific embodiments, it is a 6-membered ring. The term "aryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are shared between two adjacent rings, at least one of which is aromatic, and the other cyclic rings can be, for example, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and/or heterocyclyl. Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.

The term "carbamate" is art-recognized and refers to the group <img file="JP7720102B2_D0024.tif" /> (In the formula, R^xand R^yindependently represent hydrogen or a hydrocarbyl group, or R^xand R^ytogether with the atom to which they are attached complete a heterocycle having 4 to 8 atoms in the ring structure).

As used herein, the term "cycloalkyl" refers to a non-aromatic saturated or unsaturated ring in which each atom of the ring is carbon. In certain embodiments, the cycloalkyl ring contains 3 to 10 atoms, and more particularly, 5 to 7 atoms.

The term "carbonate" is art-recognized and refers to the group -OCO₂-R^xIn the formula, R^xrepresents a hydrocarbyl group.

As used herein, the term "carboxy" refers to a group of the formula -CO₂H.

As used herein, the term "ester" refers to the group -C(O)OR^xIn the formula, R^xrepresents a hydrocarbyl group.

As used herein, the term "ether" refers to a hydrocarbyl group bonded to another hydrocarbyl group through an oxygen atom. Thus, the ether substituent of a hydrocarbyl group can be hydrocarbyl-O-. Ethers can be symmetrical or asymmetrical. Examples of ethers include, but are not limited to, heterocycle-O-heterocycle and aryl-O-heterocycle. Ethers include "alkoxyalkyl" groups, which can be represented by the general formula alkyl-O-alkyl.

The term "guanidinyl" is art-recognized and refers to a group having the general formula <img file="JP7720102B2_D0025.tif" /> (In the formula, R^xand R^yindependently represent hydrogen or hydrocarbyl).

As used herein, the terms "halo" and "halogen" mean halogen and include chloro, fluoro, bromo, and iodo.

As used herein, the terms "hetaralkyl" and "heteroaralkyl" refer to an alkyl group substituted with a hetaryl group.

The terms "heteroaryl" and "hetaryl" include substituted or unsubstituted aromatic monocyclic ring structures, in certain particular embodiments, 5- to 7-membered rings, more particularly 5- to 6-membered rings, which ring structures contain at least one heteroatom, in some embodiments, 1 to 4 heteroatoms, and more particularly, 1 or 2 heteroatoms. The terms "heteroaryl" and "hetaryl" also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are shared between two adjacent rings, at least one of which is heteroaromatic, and the other cyclic rings can be, for example, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and/or heterocyclyl. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, pyrimidine, and the like.

The term "heteroatom" as used herein means an atom of any element other than carbon or hydrogen. Typical heteroatoms are nitrogen, oxygen, and sulfur.

The terms "heterocyclyl," "heterocycle," and "heterocyclic" refer to substituted or unsubstituted non-aromatic ring structures, in certain embodiments 3- to 10-membered rings, more particularly 3- to 7-membered rings, which ring structures contain at least one heteroatom, in some embodiments 1-4 heteroatoms, and in more particular embodiments 1 or 2 heteroatoms. The terms "heterocyclyl" and "heterocyclic" also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are shared between two adjacent rings, at least one of which is heterocyclic, e.g., the other cyclic rings can be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and/or heterocyclyl. Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.

As used herein, the term "heterocyclylalkyl" refers to an alkyl group substituted with a heterocycle group.

As used herein, the term "hydrocarbyl" refers to a group that is bonded through a carbon atom that does not have an =O or =S substituent, and generally has at least one carbon-hydrogen bond and a primarily carbon backbone, but may optionally contain heteroatoms. Thus, groups such as methyl, ethoxyethyl, 2-pyridyl, and trifluoromethyl are considered hydrocarbyl for purposes herein, while substituents such as acetyl (which has an =O substituent on the bonded carbon) and ethoxy (which is bonded through an oxygen rather than a carbon) are not considered hydrocarbyl. Hydrocarbyl groups include, but are not limited to, aryl, heteroaryl, carbocyclic, heterocyclic, alkyl, alkenyl, alkynyl, and combinations thereof.

As used herein, the term "hydroxyalkyl" refers to an alkyl group substituted with a hydroxy group.

The term "lower," when used in conjunction with chemical moieties such as acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy, is meant to include groups having 10 or fewer, and in certain embodiments, 6 or fewer, non-hydrogen atoms in the substituent. "Lower alkyl," for example, refers to alkyl groups containing 10 or fewer, and in certain embodiments, 6 or fewer, carbon atoms. In certain embodiments, the acyl, acyloxy, alkyl, alkenyl, alkynyl, and alkoxy substituents defined herein, whether appearing alone or in combination with other substituents, such as hydroxyalkyl and aralkyl (where, for example, atoms in aryl groups are not counted when counting carbon atoms in an alkyl substituent), are lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, and lower alkoxy, respectively.

The terms "polycyclyl," "polycycle," and "polycyclic" refer to two or more rings (e.g., cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and/or heterocyclyl) in which two or more atoms are shared between two adjacent rings, e.g., the rings are "fused rings." Each of the rings of a polycycle can be substituted or unsubstituted. In certain embodiments, each ring of a polycycle contains 3 to 10, more particularly 5 to 7, atoms in the ring.

The term "substituted" refers to a moiety having substituents replacing a hydrogen on one or more carbons of the backbone. It is understood that the term "with" includes the implicit proviso that such substitution is in accordance with the allowed valences of the substituted atom and substituents and that the substitution results in a stable compound, e.g., a compound that does not undergo spontaneous transformation by rearrangement, cyclization, elimination, etc., under the conditions in which the compound will be used. As used herein, the term "substituted" is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, heteroatoms, such as nitrogen, can have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatom. Substituents can include any of the substituents described herein, for example, halogen, hydroxyl, carbonyl (such as keto, carboxy, alkoxycarbonyl, formyl, or acyl), thiocarbonyl (such as thioester, thioacetate, or thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aralkyl, or aromatic or heteroaromatic moieties. Those skilled in the art will understand that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.

Unless specifically stated as "unsubstituted," references herein to chemical moieties should be understood to include substituted variants. For example, reference to an "aryl" group or moiety implicitly includes both substituted and unsubstituted variants.

The term "sulfate" is art-recognized and refers to the group -OSO₃H or a pharmaceutically acceptable salt thereof.

The term "sulfonamide" is art-recognized and can be represented by the general formula <img file="JP7720102B2_D0026.tif" /> (In the formula, R^xand R^yindependently represent hydrogen or hydrocarbyl).

The term sulfoxide is art-recognized and refers to the group S(O)R^xIn the formula, R^xrepresents a hydrocarbyl.

The terms "sulfo" or "sulfonate" are art-recognized and refer to the group -SO₃H or a pharmaceutically acceptable salt thereof.

The term "sulfone" is art-recognized and refers to the group -S(O)₂-R^xIn the formula, R^xrepresents a hydrocarbyl.

As used herein, the term "thioalkyl" refers to an alkyl group substituted with a thiol group.

As used herein, the term "thioester" refers to the group -C(O)SR^xor -SC(O)R^xIn the formula, R^xrepresents a hydrocarbyl.

As used herein, the term "thioether" is equivalent to an ether where the oxygen is replaced with a sulfur.

The term "urea" is art-recognized and has the general formula <img file="JP7720102B2_D0027.tif" /> (In the formula, R^xand R^yindependently represent hydrogen or hydrocarbyl).

The compounds of the invention are generally synthesized using standard synthetic chemistry techniques, for example, using the methods illustrated in the Examples section below. Other useful synthetic techniques are described in, for example, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7th Edition, (Wiley, 2013); Carey and Sundberg, Advanced Organic Chemistry, 4th Edition, Volumes A and B (Plenum 2000, 2001); Fiesers' Reagents for Organic Synthesis, Volumes 1-27 (Wiley, 2013); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and supplements (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-81 (Wiley, 2013); and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989) (all of which are incorporated by reference in their entirety). These compounds are usually synthesized using starting materials that are generally available from commercial suppliers or are easily prepared using methods well known to those skilled in the art. For example, Fiesers' Reagents for See Organic Synthesis, volumes 1-27 (Wiley, 2013) or Beilsteins Handbuchder organischen Chemie, 4th edition, including supplements, Springer-Verlag, Berlin.

When referring to components of the compounds of the present invention, the term "residue derived from" can be used to describe a residue formed by the reaction of a first reactive functional group on a first component with a second reactive functional group on a second component to form a covalent bond. In an exemplary embodiment, an amine group on a first component can react with an activated carboxyl group on a second component to form a residue containing one or more amide moieties. Other permutations of first and second reactive functional groups are encompassed by the present invention. For example, copper-catalyzed or copper-free reaction of an azide-substituted first component with an alkyne-substituted second component yields a triazole-containing residue via the well-known "click" reaction understood by those skilled in the art. Kolb et al. (2001) Angew. Chem. Int. Ed. Engl. 40:2004; Evans (2007) Aus. J. Chem. 60:384. Exemplary methods for creating non-peptide fluorescent imaging probes using the "click" reaction are provided in PCT International Publication No. WO2012/118715. It is within the skill of the art to adapt these methods to produce or modify the presently claimed compounds.

Those skilled in the art understand that protecting groups are reversibly attached to desired positions of molecules to control the reaction of other agents at those positions. Protecting groups useful in the practice of the present invention are well known in the art. For example, see Greene's Protective Groups in Organic Synthesis, 4th Edition, by PGM Wuts and TW Greene (Wiley-Interscience, 2006); and Protecting Groups by P. Kocienski (Thieme, 2005).

L of this compound₁The group L is a linker group that connects the detectable element D to the target element. This group can be any suitable linker, as will be appreciated by those skilled in the art.₁The group is preferably an alkyl linker group, which is optionally substituted, and further, carbons in the linker are optionally replaced by heteroatoms to the extent that the resulting structure is chemically stable. Such substitutions and replacements should be understood to include ethers, thioethers, disulfides, esters, amides, carbonates, carbamates, and the like, as intervening groups in the linker. Preferred linkers range in length from 5 to 40 bonds and may be branched, linear, or contain rings. In some cases, the linker may contain double bonds. They may be hydrophobic or hydrophilic, as desired, depending on specific requirements.

L₁It should further be understood that the linkage between the group and the detectable element D can be any suitable chemical linkage as understood by one of ordinary skill in the art. For example, the present compounds can in some cases be conveniently prepared by including in the detectable element precursor a moiety that is reactive with a particular chemical group, such as an amino group, a thiol group, etc. The detectable element can then be readily attached to the target element via reaction of this group on the target element. Thus, even if the structural details of the linkage are not explicitly set forth, these types of linkages are understood to be within the scope of the disclosed compounds.

AA of this compound₁The groups may independently be any natural or unnatural amino acid side chain, as will be appreciated by those of skill in the art. In a preferred embodiment, AA₁The group is an aralkyl amino acid side chain, optionally substituted with 1 to 3 A groups. In an even more preferred embodiment, the AA₁The group is a phenylalanine side chain.

In preferred compounds, the U group is O.

The detectable element of the compounds, in certain embodiments, is a fluorescent label, a radioactive label, a chelator, etc. Examples of radioactive labels and chelators suitable for use in these compounds are described in PCT Publication No. WO 2009/124265.

In a preferred embodiment of the present compound, the detectable element is a fluorescent label. As known to those skilled in the art, fluorescent labels emit electromagnetic radiation, preferably visible light, when stimulated by absorption of incident electromagnetic radiation. A variety of fluorescent labels are commercially available, including labels with reactive moieties useful for attaching the label to reactive groups such as amino groups, thiol groups, etc. See, for example, The Molecular Probes, 1999, 1999, 1999, 1999, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063,^(R) See Handbook-A Guide to Fluorescent Probes and Labeling Technologies.

An example of a fluorescent label is fluorescein, which has been widely used in immunofluorescence labeling. Fluorescein is a xanthene dye with an absorption maximum at 495 nanometers. A related fluorophore is Oregon Green, a fluorinated derivative of fluorescein.

In some embodiments, the fluorescent label used in the detectable element of the compound of the present invention may be a pH-dependent fluorophore. For example, such fluorescent labels, such as those used in the compounds labeled "LES12" and "LES13" shown below, exhibit fluorescence spectra that depend on the pH of the label's environment, as will be understood by those skilled in the art, and thus may be useful for reporting information about the label's environment after a reaction, such as the location or type of protease labeled by the reactive compound. The pH-dependent fluorescence of various labels that can be usefully included in the detectable element of the compound is well known. See, for example, The Molecular Probes^(R) See Handbook-A Guide to Fluorescent Probes and Labeling Technologies.

Other exemplary fluorescent labels suitable for use in the present compounds are boradiaza-indecene, rhodamine, and cyanine dyes. In particular, boradiaza-indecene dyes are represented by 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene and are known as BODIPY® dyes. Various derivatives of these dyes are known and may be suitable for use as detectable elements in the compounds of the present disclosure. See, for example, Chen et al. (2000) J. Org. Chem. 65:2900-2906.

Another class of fluorescent labels usefully employed in the compounds of the present invention are the IRDye infrared dyes available from Li-Cor (www.licor.com). Non-limiting examples of these dyes are IRDye800CW, IRDye680RD, IRDye680LT, IRDye750, IRDye700DX, IRDye800RS, and IRDye650.

Rhodamine dyes are a class of dyes based on the rhodamine ring structure. Rhodamines include tetramethylrhodamine (TMR), a very common fluorophore for preparing protein conjugates, especially antibody and avidin conjugates, and carboxytetramethylrhodamine (TAMRA), a dye commonly used in oligonucleotide labeling and automated nucleic acid sequencing. Rhodamines have been established as natural adjuncts to fluorescein-based fluorophores, providing longer wavelength emission maxima and thus opening up opportunities for multicolor labeling or staining.

The sulfonated rhodamine series of fluorophores, known as Alexa Fluor dyes, are also included in the rhodamine dye group. A dramatic advance in modern fluorophore technology is exemplified by the Alexa Fluor dyes introduced by Molecular Probes. These sulfonated rhodamine derivatives exhibit higher quantum yields for intense fluorescence emission than spectrally similar probes and possess several additional improved features, including high photostability, absorption spectra compatible with common laser lines, pH insensitivity, and high water solubility.

Cyanine dyes represent a family of related dyes, Cy2, Cy3, Cy5, Cy7, and their derivatives, based on a partially saturated indole nitrogen heterocyclic nucleus with two aromatic units linked via a polyalkene bridge of varying carbon numbers. These probes exhibit fluorescence excitation and emission profiles similar to many traditional dyes, such as fluorescein and tetramethylrhodamine, but with enhanced water solubility, photostability, and higher quantum yields. Most cyanine dyes are more environmentally stable than their traditional counterparts, making their fluorescence emission intensity less sensitive to pH and organic mounting media. In a similar manner to Alexa Fluor, the excitation wavelengths of the Cy series of synthetic dyes are specifically tuned for use with common laser and arc discharge sources, and their fluorescence emission can be detected with conventional filter combinations. Cyanine dyes are readily available as reactive dyes or fluorophores. Cyanine dyes are generally classified as Alexa Fluor dyes. They have a broader absorption spectrum than members of the Fluor family, making these dyes somewhat more versatile in the choice of laser excitation source for confocal microscopy.

In a preferred embodiment, the detectable moiety of the compound is the cyanine dye, Cy5.

In some embodiments, the detectable moiety is indocyanine green (ICG) or a residue of indocyanine green: <img file="JP7720102B2_D0028.tif" /> Benzoindole dyes such as benzoindole dyes include indocyanine green (ICG), benzoindole dyes such as benzoindole dyes (BG), benzoindole dyes (BG), and benzoindole dyes (BG). Indocyanine green is used in a variety of medical diagnostic applications, such as in the monitoring and imaging of certain cardiac, hepatic, ocular, and circulatory conditions. Advantageously, indocyanine green and related compounds exhibit absorption and emission spectra in the near-infrared region. For example, ICG absorbs primarily between 600 and 900 nm and emits primarily between 750 and 950 nm. These wavelengths are capable of penetrating biological tissues, thereby enabling imaging of these tissues using ICG and related compounds. Furthermore, the long-term and widespread use of ICG in medical diagnostic research attests to the biocompatibility of these compounds.

Thus, in some embodiments, the detectable element has the structure: <img file="JP7720102B2_D0029.tif" /> (wherein o is an integer of 1 to 4; R₂is C optionally substituted with sulfonate or carbonate₂~C₈is an alkyl group;₃are independently, C₁~C₆is an alkyl group; L₄is an optionally substituted alkyl linker, wherein each carbon atom is optionally replaced with a heteroatom.

More specifically, benzoindole dyes have the structure: <img file="JP7720102B2_D0030.tif" /> The benzoindole-containing dyes can be synthesized, for example, as described in Zhang et al. (2005) Chem. Commun. 2005:5887 (DOI: 10.1039/b512315a). See also, for example, U.S. Patent Application Publication No. 2009/0214436A1.

In some embodiments, L₄can be an optionally substituted alkyl linker, where each carbon atom is optionally replaced with a heteroatom.

In some embodiments, it may be beneficial to include multiple fluorescent labels, radioactive labels, chelators, etc., in the detectable element of the compounds of the invention. For example, the exemplary compounds labeled "LES12" and "LES13" below contain two different fluorescent labels within a single detectable element. Such multiple labeling can be achieved using conventional coupling chemistry as will be understood by those skilled in the art. For example, the fluorescent labels in the "LES12" and "LES13" compounds were linked using "click" chemistry. An example of a useful intermediate compound in the synthesis of compounds containing multiple labels within a detectable element via "click" chemistry is shown below ("WL938"). This compound contains an azide group and can therefore easily react with an appropriate alkyne-containing reagent in a "click" reaction. The positions of the alkyne and azide groups can also be reversed, if desired, as will be understood by those skilled in the art.

The ether-linked leaving element L of the present compounds can affect the reactivity of the compounds with their target enzyme active sites and can also affect the specificity of targeting to a particular enzyme. The ether linkage of the leaving element in these compounds contrasts with the ester linkage of other activity-based probes, such as acyloxymethyl ketones (AOMK). For example, ether-linked leaving elements, such as phenol-ether-linked leaving elements, can provide improved stability in vivo over ester-linked probes or other types of probes.

In some embodiments, the ether-linked leaving element of the present compounds comprises a quencher. The term "quencher" refers to a chemical entity that modulates the emission of a fluorophore. In some cases, the quencher may itself be a fluorescent molecule that fluoresces at a characteristic wavelength different from that of the label it quenches. Thus, a fluorophore can act as a quencher when appropriately coupled to another dye, or vice versa. In these situations, an increase in fluorescence from the acceptor molecule at a wavelength different from that of the donor label can independently report the interaction of the labeled compound with its environment, such as the active site of a target enzyme. In some cases, the quencher does not itself fluoresce (i.e., the quencher is a "dark acceptor"). Such quenchers include, for example, dabcyl, methyl red, and QSY diarylrhodamine dyes. In particular, dabcyl (4-dimethylamino-phenylazo)benzoate) is a common dark quencher widely used in many assays, such as "molecular beacons" for DNA detection. U.S. Patent No. 5,989,823. The BHQ series of diazo dyes, referred to as "black hole quenchers," offer a wide range of absorption that overlaps well with the emission of many fluorophores. PCT International Publication No. WO 01/86001. The QSY series dyes from Molecular Probes are another example of dark quencher dyes that are widely used as quenching reagents in many bioassays. U.S. Patent No. 6,399,392.

In particular, QSY7 is a non-fluorescent diarylrhodamine derivative. U.S. Patent Application Publication No. 2005/0014160. QSY21 is a non-fluorescent diarylrhodamine chromophore with strong absorption in the visible spectrum and is an effective fluorescence quencher. Further examples of fluorophore/quencher pairs are described in U.S. Patent Application Publication No. 2004/0241679.

IRDye QC-1 (available from Li-Cor) is another example of a non-fluorescent dye suitable for use as a quencher in the present compounds. It efficiently quenches fluorescence from a wide range of fluorophores, including those ranging in wavelength from the visible to the near-infrared.

In some embodiments of the compounds, the leaving group element, L, is L₂-L₃-Q(where L₂is a phenoxy group, and L₃is a linker and Q comprises a quencher. Leaving group elements include, for example, <img file="JP7720102B2_D0031.tif" /> where each Y is independently an electron-withdrawing group or hydrogen. In such compounds, each Y can independently be a halogen or hydrogen. In specific compounds, the L group can be, for example, <img file="JP7720102B2_D0032.tif" /> is.

The above desorption element L₃The linker group can be any suitable linker, as will be appreciated by those skilled in the art.₃The linker group may be, for example, the L₁It can be a group.

In other specific compounds, the L group is, for example, <img file="JP7720102B2_D0033.tif" /> wherein R comprises a QSY quencher and n is an integer from 1 to 8. In specific embodiments, the QSY quencher is a hydrophilic quencher such as, for example, a sulfo-QSY quencher.

In some specific embodiments, compounds of the present disclosure have formula (II): <img file="JP7720102B2_D0034.tif" /> It has the following structure.

In some embodiments, L₃-Q is <img file="JP7720102B2_D0035.tif" /> (wherein R comprises a QSY quencher or a QC-1 quencher; and n is an integer of 1 to 16.) More specifically, the QSY quencher is a hydrophilic quencher such as, for example, a sulfo-QSY quencher.

In some embodiments, the QC-1 quencher has the structure: <img file="JP7720102B2_D0036.tif" /> It has.

In some more specific embodiments, the compounds of the present disclosure have formula (III): <img file="JP7720102B2_D0037.tif" /> It has the following structure.

In these embodiments, m and n are independently integers from 1 to 16.

In some embodiments, R comprises QSY21 or sulfo-QSY21 and D is Cy5.

Alternatively, R comprises a QC-1 quencher and D comprises a benzoindole dye.

In specific embodiments of formula (III), R is <img file="JP7720102B2_D0038.tif" /> and D is <img file="JP7720102B2_D0039.tif" /> is.

Even more specifically, the compound has the structure: <img file="JP7720102B2_D0040.tif" /> It has.

Other specific non-limiting compound embodiments of the present invention are <img file="JP7720102B2_D0041.tif" /> where R = QSY21 and n = 6; R = sulfo-QSY21 and n = 6; R = QSY21 and n = 2; R = sulfo-QSY21 and n = 2.

In another aspect, the present invention provides a pharmaceutical composition comprising the compound of the present invention and a pharmaceutically acceptable carrier.Such a composition is useful, for example, in imaging tissue in animals, and is further useful for evaluating the activity of enzymes, such as protease enzymes, in animals.In particular, for the compound of the present invention that labels cathepsin, the pharmaceutical composition can be useful as a tool for non-invasive optical imaging of cancer cells.

Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline, or other solvents or vehicles such as glycols, glycerol, oils such as olive oil, or injectable organic esters. In certain embodiments, when such pharmaceutical compositions are intended for human administration, the aqueous solutions are pyrogen-free or substantially pyrogen-free. Excipients can be selected, for example, to cause delayed release of the drug or to selectively target one or more cells, tissues, or organs. Pharmaceutical compositions can be in dosage unit form, such as tablets, capsules, sprinkle capsules, granules, powders, syrups, suppositories, injections, etc. The composition can also be present in a transdermal delivery system, such as a skin patch.

Pharmaceutically acceptable carriers can contain, for example, physiologically acceptable agents that stabilize or enhance the absorption of the compounds of the present invention. Such physiologically acceptable agents include, for example, carbohydrates such as glucose, sucrose, or dextran, antioxidants such as ascorbic acid or glutathione, chelating agents, low-molecular-weight proteins, or other stabilizers or excipients. The selection of a pharmaceutically acceptable carrier containing a physiologically acceptable agent depends, for example, on the route of administration of the composition. Pharmaceutical compositions can also contain liposomes or other polymer matrices that may incorporate, for example, the compounds of the present invention. For example, liposomes composed of phospholipids or other lipids are non-toxic, physiologically acceptable, and metabolizable carriers that are relatively easy to prepare and administer.

The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions and/or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response or other problem or complication, commensurate with a reasonable benefit/risk ratio.

As used herein, the phrase "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, that is involved in carrying or transporting the compound from one organ or body part to another. Each carrier must be "acceptable" in the sense of being compatible with the other components of the formulation and not harmful to the patient. Some examples of materials that can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository wax; (9) peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and These include oils such as soybean oil; (10) glycols such as propylene glycol; (11) polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer; and (21) other non-toxic compatible substances used in pharmaceutical preparations. See Remington: The Science and Practice of Pharmacy, 20th Edition (ed. Alfonso R. Gennaro), 2000.

Pharmaceutical compositions comprising the compounds of the present invention can be administered to a subject by any of several routes of administration, including, for example, oral (e.g., liquids such as aqueous or non-aqueous solutions or suspensions, tablets, boluses, powders, granules, pastes for application to the tongue); sublingual; anal, rectal, or vaginal (e.g., as pessaries, creams, or foams); parenteral (e.g., as sterile solutions or suspensions, including intramuscular, intravenous, subcutaneous, or intrathecal); nasal; intraperitoneal; subcutaneous; transdermal (e.g., as a patch applied to the skin); or topical (e.g., as a cream, ointment, or spray applied to the skin). The compounds can also be formulated for inhalation. In certain embodiments, the compounds of the present invention can be easily dissolved or suspended in sterile water. Details of suitable routes of administration and compositions suitable therefor can be found, for example, in U.S. Patent Nos. 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970 and 4,172,896 and the patents cited therein.

Labeling and Visualization Methods In another aspect, the present invention provides a method for visualizing a tumor in an animal, comprising administering to the animal a composition of the present invention.

In yet another aspect, the present invention provides a method for visualizing a tumor in an animal, comprising administering a composition of the present invention to the animal and measuring a detectable signal generated in the animal by reaction of the composition with a cathepsin cysteine protease, wherein the detectable signal is associated with a tumor in the animal.

In some method embodiments, the detectable signal is a fluorescent signal. In some embodiments, the fluorescent signal occurs in the vicinity of the tumor.

Administration of peptide imaging agents to animals is well understood by those of skill in the art. In a preferred embodiment, the agent is administered by injection, although any other suitable means of administration is considered within the scope of the present invention.

The method of the present invention is directed to labeling and visualization of proteases, particularly cysteine proteases, in animals. Suitable animals include animals that express cysteine proteases, particularly in tumor cells. In a preferred embodiment, the animal is a mammal. In a highly preferred embodiment, the animal is a human. In another preferred embodiment, the animal is a livestock animal or a pet.

In some embodiments, the methods of the present invention include measuring a detectable signal generated in an animal. Methods for measuring a detectable signal include, but are not limited to, imaging methods, such as fluorescent imaging. In some embodiments, the fluorescent imaging system is, for example, a Xenogen IVIS 100 system, although any suitable imaging system can be used.

It will be readily apparent to those skilled in the art that other suitable modifications and adaptations can be made to the methods and applications described herein without departing from the scope of the invention or any embodiment thereof. While the invention has been described in detail herein, it will be more clearly understood by reference to the following examples. These examples are included herein for illustrative purposes only and are not intended to limit the invention.

<p>Synthesis and Characterization of Quenched Fluorescent Cysteine Cathepsin Imaging Probes Containing a Novel Phenoxymethylketone (PMK) Electrophile. The goal of this study was to develop a qABP with overall improved in vivo properties compared to existing qABPs that could be used for noninvasive optical imaging of cancer. Therefore, we decided to optimize the three key elements of the probe: the quencher, the linker, and the electrophilic "warhead." One of the most significant drawbacks of cysteine cathepsin qABPs reported to date is their relatively poor aqueous solubility. Therefore, to improve the water solubility of the probe and thereby its biodistribution, we incorporated a sulfonate group into the QSY21 quencher (Xing et al. (2005) J. Am. Chem. Soc.). 127:4158-9). The length of the spacer connecting the electrophile and quencher was also varied to decrease the lipophilicity of qABP. Finally, new electrophiles were explored to increase the range of potential cathepsin targets. Because several members of the cysteine cathepsin family are upregulated in various cancers (Mohamed and Sloane (2006) Nat. Rev. Cancer (2006) 6:764-75), brighter fluorescent signals in tumors are expected if the probe targets a broad range of cysteine cathepsin activity. To obtain more pan-reactive probes, the size of the electrophile was reduced and its reactivity was increased. It has previously been shown that 2,3,5,6-tetrafluoro-substituted phenoxymethyl ketone (PMK) electrophiles have greater reactivity toward cysteine dipeptidyl aminopeptidases compared with 2,6-dimethylbenzoic acid-derivatized acyloxymethyl ketones (AOMK). Deu et al. (2010) Chem. Biol. 17:808-819. The smaller size of PMK may also increase pan-reactivity because some of the binding grooves of cysteine cathepsins are sterically restricted. Blum et al. (2005) Nat. Chem. Biol. 1:203-9; Blum et al. (2007) Nat. Chem. Biol. 3:668-77; Paulick and Bogyo (2011) ACS Chem. Biol. 6:563-72. Furthermore, phenolic ethers are expected to be more stable in vivo compared to AOMK electrophiles, which contain ester bonds that can be cleaved by esterases.</p><p>As a starting point for this study, seven analogs (28) of qABP GB137 (1) were synthesized. Blum et al. (2007) Nat. Chem. Biol. Vol. 3: pp. 668-77; PCT International Publication No. WO2014/145257. (Figure 1A) These compounds represent all combinations of two electrophiles, two quenchers, and two linker lengths. All probes were synthesized using an optimized solution chemistry-based procedure, as described in Scheme 1 below and the associated description. Probe specificity and potency were initially tested by labeling intact RAW264.7 cells (a murine leukemia monocyte-macrophage cell line) (Figure 1B). Several trends were observed in the probe properties. All sulfo-QSY21-functionalized qABPs (2, 4, 6, and 8) showed stronger overall cathepsin labeling compared to the more hydrophobic QSY21-containing probes (1, 3, 5, and 7). Interestingly, changing the spacer length from a hexyl to an ethyl linker did not dramatically affect the labeling profile. Perhaps the most striking observation was that qABPs bearing PMK electrophiles exhibited broader cysteine cathepsin labeling profiles compared to their AOMK counterparts. Probes 58 exhibited robust cathepsin X labeling, while sulfo-QSY21-functionalized probes 6 and 8 were capable of labeling the higher molecular weight proform of cathepsin L. The identity of the fluorescently labeled cathepsins was determined by immunoprecipitation (Figure 4A). Several other interesting trends were observed when performing titration labeling experiments in live RAW cells (Figures 1C, 1D; Figures 4B, 4C). The most hydrophobic qABPs (1 and 5) reached a maximum of reduced labeling intensity at 0.5 μM, suggesting that their reduced water solubility leads to precipitation of the probes at higher concentrations. A shorter spacer length appears beneficial, as all probes with ethyl spacers gave brighter labeling compared to their hexyl-containing counterparts. Clear differences in selectivity are observed when comparing AOMK with PMK. AOMK qABP preferentially labels cathepsins S and L, and only at higher concentrations labels cathepsin B. Surprisingly, AOMK qABPs 2-4 label cathepsin X, despite previous studies showing that several other related AOMKs are unable to label this target (Paulick and Bogyo (2011) ACS Chem. Biol. 6:563-72). PMK qABP also labels all target cysteine cathepsins with equal intensity, even at lower probe concentrations. Together, these experiments demonstrate that increased hydrophilicity improves labeling intensity and that the novel PMK qABP has a broader, more pan-cysteine cathepsin labeling profile.</p><p>PMK qABP8 was optimal in terms of overall labeling intensity and broad cathepsin reactivity, so further in We decided to proceed with this probe for in vivo studies. To further define target selectivity, RAW cell lysates were labeled with increasing concentrations of qABP8 at pH 5.5. These results demonstrated that the probe was most potent for cathepsins B and X, with labeling observed at concentrations as low as 5 nM. However, labeling of all cathepsins (B, S, L, and X) saturated at 500 nM of probe (Figure 2A). When the probe was used for time-lapse labeling of live RAW cells at a set concentration of 500 nM, rapid saturation of cathepsin X was observed, followed by slower labeling of cathepsins S, L, and B, with an increase in cathepsin B labeling signal even at 120 min (Figure 2B). These data indicate that the probe may have the most rapid access to the cathepsin X pool, likely due to its localization within the cell or on the cell surface. These results also indicate that cathepsins B and X may reside in alternating locations in cells that can be accessed by the probe to different degrees. To test the stability of the new PMK probe, we examined the effect of serum exposure on labeling in RAW cells (Figure 1C). Four hours of serum pre-exposure to the original AOMK probe 1 resulted in a nearly 70% reduction in target labeling, whereas more than 80% labeling was maintained for PMK qABP8. Pretreatment of cells with the cysteine cathepsin inhibitor JPM-OEt also blocked more than 90% of this labeling. Given the stability and improved labeling properties of the PMK probe, we next performed live-cell fluorescence microscopy studies. These results confirmed that the probe generated a bright, specific labeling signal and that the majority of probe-labeled cathepsins were present in lysosomes (Figure 2D).</p><p>Given the positive live-cell labeling properties of the new PMK electrophiles, the best-performing PMK qABPs, 2, 6, and 8, were tested in an orthotopic mouse model of breast cancer. Tao et al. (2008) BMC Cancer 8:228. Additionally, these PMK probes were compared with the original AOMK probe 1 (Figures 3A-3F and 5A-5F). 4T1 cells were implanted into mammary fat pads 2 and 7 of Balb/c mice, and tumor growth was monitored. Once tumors were established, mice were injected with an equimolar amount of qABP (20 nmol) through the tail vein, and Cy5 fluorescence was noninvasively imaged over time (Figures 3A and 3B). These results reaffirmed the superiority of qABP8. Robust tumor-specific activation of fluorescence could be observed for probe 8, specifically in the tumor region, with high overall contrast. This signal continued to increase over time until the end of the time course. Ultimately, probe 8 achieved a greater than 20-fold enhancement of tumor-specific fluorescence signal compared to probe 1. Good tumor-specific contrast was also observed for probe 6 and to a lesser extent for probe 2, although both were still more than 10-fold greater than probe 1 (Figures 5A and 5B). After the time course was completed, tumors were excised and tumor fluorescence was examined. in vivo, followed by homogenization and analysis of fluorescently labeled proteins by SDS-PAGE (Figures 3C and 5C). Quantification of in vivo fluorescence and total cysteine cathepsin labeling showed trends similar to those seen in noninvasive optical imaging studies (Figures 3D and 5D). To determine the cellular source of probe fluorescence, immunofluorescent staining of tumor tissue sections from probe-labeled mice was performed using the macrophage marker CD68 (Figures 3E and 5E). Cy5 fluorescence localized to CD68-positive cells; however, not all CD68-positive cells were also probe 8-positive, indicating different activation states of tumor-associated macrophages. More detailed analysis using confocal laser scanning microscopy (CLSM) confirmed that all cells positive for probe 8 were CD68-positive, but that probe-labeled cathepsin and CD68 signals did not colocalize to the same vesicles (Figures 3F and 5F). Taken together, these data suggest that increasing the hydrophilicity of the quencher, shortening the spacer, and introducing more reactive and less sterically restricted nucleophilic traps may contribute to the broader reactivity of cysteine cathepsins and in It is confirmed that this resulted in a qABP with overall improved in vivo properties.</p><p>Although very distinct functions have been described for some cysteine cathepsin family members (Conus and Simon (2010) Swiss Med. Wkly. 140:w13042), other roles overlap, and changes in the activity of one cathepsin can affect the activity of others. For example, loss of cathepsin B is compensated for by increased activity of cathepsin X (Sevenich et al. (2010) Proc. Natl. Acad. Sci. USA 107:2497-502), and upregulation of cathepsin B leads to downregulation of cathepsin L (Gopinathan et al. (2012) Gut 61:877-84). Therefore, broad-range probes are valuable because they facilitate the readout of multiple cysteine cathepsins in a single experiment and allow comparison of the activities of individual cathepsins relative to each other. The utility of such pan-reactive ABPs has been demonstrated by the pan-serine hydrolase fluorophosphonate probes (Liu et al. (1999) Proc. Natl. Acad. Sci. USA 96:14694-9) and the pan-reactive proteasome probe MV151 (Verdoes et al. (2006) Chem. Biol. 13:1217-26). Furthermore, because PMK-based qABPs are highly reactive toward cathepsin X, these scaffolds can be used to create selective qABPs for this still poorly understood cysteine cathepsin. (Paulick and Bogyo (2011) ACS Chem. Biol. 6:563-72).</p><p>In conclusion, a novel class of quenched fluorescent activity-based probes with PMK electrophiles has been synthesized, which have higher reactivity and broader selectivity compared to previously reported AOMK-based probes. Furthermore, the hydrophilicity of qABPs was increased by introducing a sulfonated quencher and shortening the spacer connecting the electrophile and quencher, resulting in higher aqueous solubility and improved in vivo properties, which lead to enhanced contrast in noninvasive optical imaging of cancer.</p><p>General Methods: All resins and reagents were purchased from commercial suppliers and used without further purification. All solvents used were UPLC grade. Reagent-grade solvents were used for all non-aqueous extractions. All moisture-sensitive reactions were performed in anhydrous solvents under positive argon pressure. Reactions were analyzed by LC-MS using an API 150EX single quadrupole mass spectrometer (Applied Biosystems). Reverse-phase HPLC was performed using an ÅKTA explorer 100 (Amersham Pharmacia Biotech) with a C18 column. NMR spectra were recorded on a Varian 400 MHz (400/100), Varian 500 MHz (500/125), or Varian Inova 600 MHz (600/150 MHz) equipped with a pulsed field gradient accessory. Chemical shifts are given in ppm (δ) relative to tetramethylsilane as the internal standard. Coupling constants are given in Hz. Fluorescent gels were scanned using a Typhoon 9400 flatbed laser scanner (GE The gels were scanned using a software program (Intelligent Imaging Innovations). Labeling intensity in the gels was quantified using Image J software. Statistical analysis was performed using Microsoft Excel, and sem was calculated by dividing sd by the square root of n. Fluorescence microscopy images were acquired with a Zeiss confocal LSM 710 and a Zeiss Axiovert 200M inverted microscope (Carl Zeiss) equipped with 10x, 40x, and 63x objectives. Slidebook software was used to control the microscope and camera and for data analysis (Intelligent Imaging Innovations).</p><p>qABP synthesis</p><p>The synthetic scheme for the synthesis of the following compounds is depicted in Scheme 1 below.</p><p>2,6-Dimethyl-4-((6-(tritylamino)hexyl)carbamoyl)benzoic acid (11a). Mono-trityl 1,6-diaminohexane acetate (9a) (117.2 mg, 0.28 mmol) was dissolved in DCM and saturated aqueous NaHCO₃Wash with Na₂SO₄The mixture was dried over 200°C and concentrated in vacuo. The amine was dissolved in DMF, HOBt monohydrate (43 mg, 0.28 mmol, 1 equiv.), EDC (54 mg, 0.28 mmol, 1 equiv.), and 2,6-dimethylterephthalic acid (10) (54.4 mg, 0.28 mmol, 1 equiv.) were added, and the reaction mixture was stirred overnight before being concentrated in vacuo. The crude material was purified by flash column chromatography (DCM 5% MeOH in DCM), then dissolved in DCM, washed with water, and concentrated in vacuo.₄The product was dried at rt to give 70 mg (0.13 mmol, 47% isolated yield).</p><p>2,6-Dimethyl-4-((2-(tritylamino)ethyl)carbamoyl)benzoic acid (11b). Mono-tritylethylenediamine acetate (9b) (97.9 mg, 0.27 mmol) was dissolved in DCM and saturated aqueous NaHCO₃Wash with Na₂SO₄The mixture was dried over 200°C and concentrated in vacuo. The amine was dissolved in DMF, HOBt monohydrate (43 mg, 0.28 mmol, 1.04 equiv.), EDC (61 mg, 0.32 mmol, 1.2 equiv.), and 2,6-dimethylterephthalic acid (10) (52 mg, 0.27 mmol, 1 equiv.) were added, and the reaction mixture was stirred overnight before being concentrated in vacuo. The crude material was purified by flash column chromatography (DCM 5% MeOH in DCM), then dissolved in DCM, washed with water, and concentrated in vacuo.₄Drying at rt gave 28 mg (0.06 mmol, 22% isolated yield).</p><p>2,3,5,6-Tetrafluoro-4-hydroxy-N-(6-(tritylamino)hexyl)benzamide (13a). Mono-trityl 1,6-diaminohexane acetate (9a) (117.2 mg, 0.28 mmol) was dissolved in DCM and saturated aqueous NaHCO₃Wash with Na₂SO₄The mixture was dried at 77°C and concentrated in vacuo. The amine was dissolved in DMF, and HOBt monohydrate (43 mg, 0.28 mmol, 1 equiv.), EDC (54 mg, 0.28 mmol, 1 equiv.), and 2,3,5,6-tetrafluoro-4-hydroxybenzoic acid (12) (59 mg, 0.28 mmol, 1 equiv.) were added. The reaction mixture was stirred overnight and then concentrated in vacuo. The crude material was purified by flash column chromatography (15% to 30% ethyl acetate in hexanes) to give 90 mg (0.16 mmol, 58% isolated yield).</p><p>2,3,5,6-Tetrafluoro-4-hydroxy-N-(2-(tritylamino)ethyl)benzamide (13b). Mono-tritylethylenediamine acetate (9b) (100 mg, 0.28 mmol) was dissolved in DCM and saturated aqueous NaHCO₃Wash with Na₂SO₄The mixture was dried at 77°C and concentrated in vacuo. The amine was dissolved in DMF, and HOBt monohydrate (43 mg, 0.28 mmol, 1 equiv.), EDC (54 mg, 0.28 mmol, 1 equiv.), and 2,3,5,6-tetrafluoro-4-hydroxybenzoic acid (12) (59 mg, 0.28 mmol, 1 equiv.) were added. The reaction mixture was stirred overnight and then concentrated in vacuo. The crude material was purified by flash column chromatography (20% to 35% ethyl acetate in hexanes) to give 90 mg (0.18 mmol, 65% isolated yield).¹H NMR (400 MHz, DMSO) δ = 8.77 (t, J=6.0, 1H), 7.39 (d, J=7.8, 6H), 7.27 (t, J=7.7, 6H), 7.17 (t, J=7.2, 3H), 3.40 - 3.35 (m, 2H), 2.86 - 2.77 (m, 1H), 2.14 - 2.04 (m, 2H). <img file="JP7720102B2_D0042.tif" /> Scheme 1. Reagents and conditions: i. EDC, HOBt, DMF. ii. a) KF, DMF. b) 1% TFA, DCM. iii. a) QSY21-NHS or sulfo-QSY21-NHS, DiPEA, DMSO. b) TFA/DCM = 1/1. c) Cy5-NHS, DiPEA, DMSO. iv. a) KF, DMF, 80°C. b) 1% TFA, DCM.</p><p>Intermediate 15. Potassium fluoride (3 mg, 52 μmol, 3 equiv.) was suspended in DMF with sonication for 5 min, followed by the addition of carboxylic acid 11a (10 mg, 19 μmol, 1.1 equiv.). The reaction mixture was stirred for 10 min, followed by the addition of chloromethyl ketone 14 (9.7 mg, 17.3 μmol, 1 equiv.). After 1.5 h, the reaction mixture was concentrated in vacuo, and the crude was dissolved in 1% TFA in DCM and stirred for 30 min before being quenched by the addition of triisopropylsilane until the solution became colorless. After coevaporation with toluene (3 times), the title compound was purified by HPLC (preparative reverse phase C₁₈Column, CH₃CN/H₂Purification with 0.1% TFA (15:85 to 55:45 over 20 min; 5 mL/min) followed by lyophilization gave 15 as a white powder (3.12 mg, 3.46 μmol, 20% over two steps).</p><p>Intermediate 16. Potassium fluoride (3 mg, 52 μmol, 3 equiv.) was suspended in DMF with sonication for 5 min, followed by the addition of carboxylic acid 11b (9.5 mg, 20 μmol, 1.1 equiv.). The reaction mixture was stirred for 10 min, followed by the addition of chloromethyl ketone 14 (10 mg, 17.9 μmol, 1 equiv.). After 1.5 h, the reaction mixture was concentrated in vacuo, and the crude was dissolved in 1% TFA in DCM and stirred for 30 min before being quenched by the addition of triisopropylsilane until the solution became colorless. After coevaporation with toluene (3 times), intermediate 16 was purified by HPLC (preparative reverse-phase C₁₈Column, CH₃CN/H₂Purification with 0.1% TFA, 15:85 to 55:45 over 20 min; 5 mL/min) followed by lyophilization gave a white powder (3.99 mg, 4.57 μmol, 26% over two steps).¹H NMR (500 MHz, CD₃OD) δ 7.80 (s, 1H), 7.42 (s, 1H), 7.35 - 7.18 (m, 10H), 5.06 (s, 2H), 4.85 - 4.78 (m, 2H), 4.42 (dd, J = 13.1, 6.2 Hz, 1H), 4.37 (dd, J = 10.1, 4.0 Hz, 1H), 3.64 (t, J = 5.7 Hz, 2H), 3.18 (t, J = 4.8 Hz, 2H), 3.12 (dd, J = 13.7, 7.0 Hz, 1H), 3.01 (t, J = 7.3 Hz, 2H), 2.94 (dd, J = 13.6, 8.9 Hz, 1H), 2.41 (s, 3H), 2.34 (s, 3H), 1.92 - 1.82 (m, 1H), 1.67 - 1.57 (m, 1H), 1.49 - 1.26 (m, 4H), 1.42 (s, 9H).</p><p>Intermediate 17. Potassium fluoride (6.3 mg, 108 μmol, 3 equiv.) was suspended in DMF with sonication for 5 min, followed by the addition of phenol 13a (21.5 mg, 39 μmol, 1.1 equiv.). The reaction mixture was stirred for 10 min, followed by the addition of chloromethyl ketone 14 (20 mg, 36 μmol, 1 equiv.). The reaction mixture was stirred at 80°C for 5 h and then concentrated in vacuo. The crude material was dissolved in 1% TFA in DCM and stirred for 30 min before being quenched by the addition of triisopropylsilane until the solution became colorless. After coevaporation with toluene (3 times), the product was purified by HPLC (preparative reverse-phase C).₁₈Column, CH₃CN/H₂Purification with O 0.1% TFA, 25:75 to 70:30 over 20 min; 5 mL/min) followed by lyophilization afforded the title compound as a white powder (16.6 mg, 17.5 μmol, 49% over two steps).¹H NMR (500 MHz, CD₃OD) δ 7.29 (m , 10H), 5.07 (s, 2H), 4.86 (m , 2H), 4.44 (m , 2H), 3.41 (t, J = 6.8, 2H), 3.10 (dd, J = 13.5, 7.0, 1H), 3.02 (t, J = 6.8, 2H), 2.97 - 2.91 (m, 3H), 1.93 - 1.81 (m, 1H), 1.73 - 1.62 (m, 4H), 1.62 - 1.53 (m, 1H), 1.51 - 1.46 (m, 4H),1.43 (s, 9H), 1.45 - 1.25 (m, 4H).</p><p>Intermediate 18. Potassium fluoride (6.3 mg, 108 μmol, 3 equiv.) was suspended in DMF with sonication for 5 min, followed by the addition of phenol 13b (19.4 mg, 39 μmol, 1.1 equiv.). The reaction mixture was stirred for 10 min, followed by the addition of chloromethyl ketone 14 (20 mg, 36 μmol, 1 equiv.). The reaction mixture was stirred at 80°C for 3 h and then concentrated in vacuo. The crude material was dissolved in 1% TFA in DCM and stirred for 30 min before being quenched by the addition of triisopropylsilane until the solution became colorless. After coevaporation with toluene (3 times), the product was purified by HPLC (preparative reverse-phase C).₁₈Column, CH₃CN/H₂Purification with O 0.1% TFA, 20:80 to 60:40 over 20 min; 5 mL/min) followed by lyophilization afforded the title compound as a white powder (15.4 mg, 17.3 μmol, 48% over two steps).¹H NMR (400 MHz, CD₃OD) δ = 7.36 - 7.12 (m, 10H), 5.05 (s, 2H), 4.86 - 4.81 (m, 2H), 4.42 - 4.37 (m, 2H), 3.64 (t, J=6.5, 2H), 3.14 (t, J=6.5, 2H), 3.08 (dd, J=13.9, 7.2, 1H), 2.99 (t, J=6.5, 2H), 2.91 (dd, J=13.9, 8.4, 1H), 1.90 - 1.78 (m, 1H), 1.62 - 1.48 (m, 1H),1.41 (s, 9H), 1.46 - 1.20 (m, 4H).</p><p>Probe 1 (GB137). Intermediate 15 (1.5 mg, 1.7 μmol) was dissolved in DMSO (50 μl), and QSY21-NHS (1.39 mg, 1.7 μmol, 1 equiv.) and DiPEA (1.5 μl, 8.5 μmol, 5 equiv.) were added. After 1 h, QSY21 amide was purified by HPLC (preparative reverse-phase C₁₈Column, CH₃CN/H₂The product was purified by 0.1% TFA (40:60 to 80:20 over 20 min; 5 mL/min) followed by lyophilization. To remove the Boc protecting group, the resulting dark blue powder was dissolved in TFA/DCM (1/1) and reacted for 30 min, followed by coevaporation with toluene (3 times) to give 2.42 mg of the corresponding TFA salt (1.6 μmol, 95% yield over two steps). The amine was dissolved in DMSO (50 μL) and Cy5-NHS (1.3 mg, 1.76 μmol, 1.1 equiv.) and DiPEA (1.4 μL, 8 μmol, 5 equiv.) were added. After 1 h, the product was purified by HPLC (preparative reverse-phase C₁₈Column, CH₃CN/H₂Purification with O 0.1% TFA, 40:60 to 75:25 over 20 min; 5 mL/min) followed by lyophilization afforded probe 1 as a dark blue powder (2.0 mg, 0.99 μmol, 62%).</p><p>Probe 2 (BMV122). Intermediate 15 (1.5 mg, 1.7 μmol) was dissolved in DMSO (50 μl), and sulfo-QSY21-NHS (1.66 mg, 1.7 μmol, 1 equiv.) and DiPEA (1.5 μl, 8.5 μmol, 5 equiv.) were added. After 1 h, sulfo-QSY21 amide was purified by HPLC (preparative reverse-phase C₁₈Column, CH₃CN/H₂The product was purified by elution with 0.1% TFA (30:70 to 70:30 over 20 min; 5 mL/min) followed by lyophilization. To remove the Boc protecting group, the resulting dark blue powder was dissolved in TFA/DCM (1/1) and reacted for 30 min, followed by coevaporation with toluene (3 times) to give 2.29 mg of the corresponding TFA salt (1.39 μmol, 81% over two steps). The amine was dissolved in DMSO (50 μL) and Cy5-NHS (1.1 mg, 1.5 μmol, 1.1 equiv.) and DiPEA (1.2 μL, 7 μmol, 5 equiv.) were added. After 1 h, the product was purified by HPLC (preparative reverse-phase C₁₈Column, CH₃CN/H₂Purification with O 0.1% TFA, 15:85 to 50:50 over 20 min; 5 mL/min) followed by lyophilization gave probe 2 as a dark blue powder (1.83 mg, 0.84 μmol, 61%).</p><p>Probe 3 (BMV145). Intermediate 16 (1.5 mg, 1.7 μmol) was dissolved in DMSO (50 μl) and QSY21-NHS (1.39 mg, 1.7 μmol, 1 equiv.) and DiPEA (1.5 μl, 8.5 μmol, 5 equiv.) were added. After 1 h, QSY21 amide was purified by HPLC (preparative reverse-phase C₁₈Column, CH₃CN/H₂The product was purified by 0.1% TFA (40:60 to 80:20 over 20 min; 5 mL/min) followed by lyophilization. To remove the Boc protecting group, the resulting dark blue powder was dissolved in TFA/DCM (1/1) and reacted for 30 min, followed by coevaporation with toluene (3 times) to give 0.86 mg of the corresponding TFA salt (0.6 μmol, 35% isolated yield over two steps). The amine was dissolved in DMSO (50 μL) and Cy5-NHS (0.5 mg, 0.66 μmol, 1.1 equiv.) and DiPEA (0.57 μL, 3.3 μmol, 5 equiv.). After 1 h, the product was purified by HPLC (preparative reverse-phase C₁₈Column, CH₃CN/H₂Purification with 0.1% TFA (40:60 to 75:25 over 20 min; 5 mL/min) followed by lyophilization afforded probe 3 as a dark blue powder (0.67 mg, 0.34 μmol, 57%).</p><p>Probe 4 (BMV146). Intermediate 16 (1.0 mg, 1.2 μmol) was dissolved in DMSO (50 μl), and sulfo-QSY21-NHS (1.25 mg, 1.2 μmol, 1 equiv.) and DiPEA (1.05 μl, 6 μmol, 5 equiv.) were added. After 1 h, sulfo-QSY21 amide was purified by HPLC (preparative reverse-phase C₁₈Column, CH₃CN/H₂The product was purified by elution with 0.1% TFA (20:80 to 80:20 over 20 min; 5 mL/min) followed by lyophilization. To remove the Boc protecting group, the resulting dark blue powder was dissolved in TFA/DCM (1/1) and reacted for 30 min, followed by coevaporation with toluene (3 times) to give 1.06 mg of the corresponding TFA salt (0.66 μmol, 55% over two steps). The amine was dissolved in DMSO (50 μL) and Cy5-NHS (0.55 mg, 0.73 μmol, 1.1 equiv.) and DiPEA (0.64 μL, 3.65 μmol, 5 equiv.). After 1 h, the product was purified by HPLC (preparative reverse-phase C).₁₈Column, CH₃CN/H₂Purification with O 0.1% TFA, 15:85 to 50:50 over 20 min; 5 mL/min) followed by lyophilization afforded probe 4 as a dark blue powder (0.63 mg, 0.3 μmol, 45%).</p><p>Probe 5 (BMV118). Intermediate 17 (1.2 mg, 1.3 μmol) was dissolved in DMSO (50 μl) and QSY21-NHS (1.0 mg, 1.3 μmol, 1 equiv.) and DiPEA (1.13 μl, 6.5 μmol, 5 equiv.) were added. After 2 h, QSY21 amide was purified by HPLC (preparative reverse-phase C₁₈Column, CH₃CN/H₂The product was purified by 0.1% TFA (40:60 to 80:20 over 20 min; 5 mL/min) followed by lyophilization. To remove the Boc protecting group, the resulting dark blue powder was dissolved in TFA/DCM (1/1) and reacted for 30 min, followed by coevaporation with toluene (3 times) to give 2.0 mg of the corresponding TFA salt (1.3 μmol, quantifiable in two steps). The amine was dissolved in DMSO (50 μL) and Cy5-NHS (1.0 mg, 1.3 μmol, 1 equiv.) and DiPEA (1.1 μL, 6.5 μmol, 5 equiv.) were added. After 1 h, the product was purified by HPLC (preparative reverse-phase C₁₈Column, CH₃CN/H₂Purification with O 0.1% TFA, 40:60 to 85:15 over 20 min; 5 mL/min) followed by lyophilization afforded probe 5 as a dark blue powder (1.91 mg, 0.94 μmol, 72%).</p><p>Probe 6 (BMV119). Intermediate 17 (1.2 mg, 1.3 μmol) was dissolved in DMSO (50 μl), and sulfo-QSY21-NHS (1.35 mg, 1.3 μmol, 1 equiv.) and DiPEA (1.13 μl, 6.5 μmol, 5 equiv.) were added. After 1 h, sulfo-QSY21 amide was purified by HPLC (preparative reverse-phase C₁₈Column, CH₃CN/H₂The product was purified by elution with 0.1% TFA (30:70 to 90:10 over 20 min; 5 mL/min) followed by lyophilization. To remove the Boc protecting group, the resulting dark blue powder was dissolved in TFA/DCM (1/1) and reacted for 30 min, followed by coevaporation with toluene (3 times) to give 1.98 mg of the corresponding TFA salt (0.9 μmol, 70% over two steps). The amine was dissolved in DMSO (50 μL) and Cy5-NHS (0.7 mg, 0.9 μmol, 1.1 equiv.) and DiPEA (0.8 μL, 4.5 μmol, 5 equiv.). After 1 h, the product was purified by HPLC (preparative reverse-phase C₁₈Column, CH₃CN/H₂Purification with O 0.1% TFA, 15:85 to 50:50 over 20 min; 5 mL/min) followed by lyophilization afforded probe 6 as a dark blue powder (1.63 mg, 0.74 μmol, 82%).</p><p>Probe 7 (BMV108). Intermediate 18 (1.2 mg, 1.3 μmol) was dissolved in DMSO (50 μl) and QSY21-NHS (1.2 mg, 1.4 μmol, 1.1 equiv.) and DiPEA (1.13 μl, 6.5 μmol, 5 equiv.) were added. After 1 h, QSY21 amide was purified by HPLC (preparative reverse-phase C₁₈Column, CH₃CN/H₂Purification was performed with 0.1% TFA, 30:70 to 70:30 over 20 min; 5 mL/min, followed by lyophilization to give a dark blue powder (1.43 mg, 0.99 μmol, 76%). The Boc protecting group was then removed in TFA/DCM (1/1) for 30 min, followed by coevaporation with toluene (3 times). The TFA salt was dissolved in DMSO (50 μl), and Cy5-NHS (0.83 mg, 1.1 μmol, 1.1 equiv.) and DiPEA (0.88 μl, 5 μmol, 5 equiv.) were added. After 1 h, the product was analyzed by HPLC (preparative reverse-phase C).₁₈Column, CH₃CN/H₂Purification with 0.1% TFA (30:70 to 70:30 over 20 min; 5 mL/min) followed by lyophilization afforded probe 7 as a dark blue powder (0.95 mg, 0.48 μmol, 49% over two steps).</p><p>Probe 8 (BMV109). Intermediate 18 (5.8 mg, 6.5 μmol) was dissolved in DMSO (100 μl). Sulfo-QSY21-NHS (9.75 mg, 10.39 μmol, 1.6 equiv.) and DiPEA (8.4 μl, 50.5 μmol, 7.8 equiv.) were added and the mixture was stirred overnight. Sulfo-QSY21 amide was purified by HPLC (preparative reverse-phase C₁₈Column, CH₃CN/H₂The residue was purified by 0.1% TFA (25:75 to 55:45 over 20 min; 5 mL/min) followed by lyophilization to give a dark blue powder. The Boc protecting group was then removed in TFA/DCM (1/1) for 30 min, followed by coevaporation with toluene (3 times). The residue was dissolved in DMSO (250 μL) and Cy5-NHS (10.5 mg, 13.9 μmol, 2.1 equiv.) and DiPEA (12 μL, 72 μmol, 11 equiv.) were added. After 4 h, the residue was purified by HPLC (preparative reverse-phase C₁₈Column, CH₃CN/H₂Purification with O 0.1% TFA, 25:75 to 45:55 over 20 min; 5 mL/min) followed by lyophilization afforded probe 8 as a dark blue powder (7.74 mg, 4.61 μmol, 71% over two steps).¹H NMR (600 MHz, CD₃CN) δ 8.12 - 8.08 (m, 1H), 8.01 - 7.93 (m, 2H), 7.89 - 7.85 (m, 2H), 7.75 (dd, J = 12.0, 1.5 Hz, 2H), 7.72 (dd, J = 8.4, 1.7Hz, 1H), 7.69 (dd, J = 8.3, 1.2 Hz, 1H), 7.66 (s, 2H), 7.62 - 7.57 (m, 2H), 7.51 (dd, J = 8.4, 5.1 Hz, 2H), 7.46 (d, J = 9.4 Hz, 2H), 7.41 - 7.35 (m, 3H), 7.24(s, 1H), 7.22 (s, 1H), 7.21 - 7.14 (m, 6H), 7.13 - 7.09 (m, 6H), 7.05 (dd, J = 8.8, 4.6 Hz, 1H), 6.39 (t, J = 12.8 Hz, 1H), 6.11 (t, J = 12.6 Hz, 1H), 4.87 (q,J = 12.7 Hz, 2H), 4.83 (dd, J = 39.7, 14.1 Hz, 2H), 4.23 - 4.12 (m, 4H), 3.93 (q, J = 7.2 Hz, 2H), 3.86 (t, J = 7.4 Hz,2H), 3.34 (dd, J = 6.7, 4.1 Hz, 2H), 3.28 - 3.15 (m, 9H), 3.04 - 2.92 (m, 3H), 2.80 - 2.74 (m, 1H), 2.45 (t, J = 11.9 Hz, 2H), 2.15 - 2.09 (m, 1H), 2.09 - 2.03(m, 2H), 1.74 - 1.58 (m, 7H), 1.57 (s, 6H), 1.55 (s, 6H), 1.49 (dd, J = 15.1, 7.4 Hz, 4H), 1.35 - 1.22 (m, 7H), 1.20 (t, J = 7.3 Hz, 3H), 1.16 - 1.12 (m, 4H). Cell culture and labeling of live cells and cell lysates.</p><p>RAW cells were cultured in DMEM (GIBCO) supplemented with 10% fetal bovine serum (FBS; GIBCO), 100 units/mL penicillin, and 100 μg/mL streptomycin (GIBCO). 4T1 cells (ATCC) were cultured in RPMI (GIBCO) supplemented with 10% fetal bovine serum (FBS; GIBCO), 100 units/mL penicillin, and 100 μg/mL streptomycin (GIBCO). All cells were maintained in a 5% CO atmosphere.₂Cells were cultured at 37°C in a humidified incubator. For intact cell labeling, cells were exposed to the probe (500x in DMSO) in culture medium and incubated for 2 hours at 37°C unless otherwise noted. Where indicated, cells were preincubated with the inhibitor JPM-OEt (500x in DMSO) for 1 hour or exposed to mouse serum (1 μl of probe stock solution in DMSO was added to 9 μl of serum) for 4 hours before addition to the cells. After labeling, cells were washed with PBS and lysed in hypotonic lysis buffer (50 mM PIPES pH 7.4, 10 mM KCl, 5 mM MgCl).₂The cells were resuspended in 2% EDTA, 2 mM EDTA, 4 mM DTT, and 1% NP-40, placed on ice for 15 minutes, and centrifuged at 4°C for 30 minutes. The supernatant was collected, and the protein concentration was determined using a BCA kit (Pierce). 40 μg of total protein was denatured by adding 4x SDS sample buffer and heating at 100°C for 3 minutes, resolved by SDS-PAGE (15%), and the labeled proteases were visualized by scanning the gels with a Typhoon imager (GE Healthcare). Labeling intensity was quantified using Image J software. For cathepsin labeling in cell lysates, cells were harvested, washed with PBS, and resuspended in citrate buffer (50 mM citrate buffer pH 5.5, 5 mM DDT, 0.5% CHAPS, 0.1% Triton X-10). After centrifugation for 15 min on ice and 30 min at 4°C, the supernatant was collected and the protein concentration was determined using a BCA kit (Pierce). 40 μg of total protein was exposed to the indicated probes (200x in DMSO) for 1 h at 37°C. 4x SDS sample buffer was added, and the proteins were denatured at 100°C for 3 min and analyzed as described above. For live cell microscopy, RAW cells were cultured at 1x10 in complete medium without phenol red.⁵Cells were seeded at a density of 1000x on 35mm glass-bottom dishes (In Vitro Scientific) and cultured overnight. Cells were exposed to either DMSO or 1μM probe (500x in DMSO) for 2 hours. Lysotracker-green (200nM final concentration, 1000x in DMSO) was added to the cells for the last hour. Where indicated, cells were pre-incubated with the inhibitor JPM-OEt (500x in DMSO) for 1 hour. Cells were imaged in both the Cy5 and FITC channels at 40x magnification using a Zeiss Axiovert 200M confocal microscope.</p><p>Animal models</p><p>All animal care and experiments were performed in accordance with current National Institutes of Health and Stanford University Institutional Animal Care and Use Committee guidelines. Female BALB/c mice (6-8 weeks old, The Jackson Laboratory) were anesthetized with 1 × 10 PBS.⁵4T1 cells (ATCC) were injected into fat pads 2 and 7 and tumor growth was monitored. 24 hours before imaging, hair in the area of interest was removed using "Nair lotion." On day 10, the indicated probes (20 nmol; 0.8 nmol g^-1) was administered via the tail vein in a volume of 100 μL (20% DMSO in PBS). After injection, mice were noninvasively imaged at the indicated time points using an IVIS 100 system (Xenogen). Images were analyzed using Living Image software (PerkinElmer). After the final time point, mice were anesthetized with isoflurane and killed by cervical dislocation. For ex vivo fluorescence measurements and evaluation of in vivo probe labeling profiles, tumors were removed and imaged using an FMT 2500 (PerkinElmer), and tissues were resuspended in citrate buffer (50 mM citrate buffer pH 5.5, 5 mM The tumors were sonicated (1 min on ice) in a 0.5% DDT solution, 0.5% CHAPS, and 0.1% TritonX. After centrifugation at 4°C for 30 min, the supernatant was collected, and the protein concentration was determined using a BCA kit (Pierce). 40 μg of total protein was denatured in SDS sample buffer at 100°C for 3 min and analyzed as described above. For immunofluorescence, excised tumors were incubated in 4% PFA solution in PBS for 6 h at 4°C, followed by overnight incubation in 30% sucrose solution, and the tissue was frozen in OCT medium. 6 μm sections were fixed in acetone, blocked with PNB blocking buffer, and incubated overnight with rat anti-mouse CD68 (1:1000; Serotec). AlexaFluor-488-conjugated goat anti-rat (1:500; Invitrogen) was incubated at room temperature for 1 h. The sections were then stained with DAPI (2 μg/mL; Invitrogen) for 5 minutes and then mounted in ProLongGold Mounting Medium (Invitrogen). Visualization was performed using a 200M microscope.</p><p>Synthesis and characterization of indocyanine green-labeled imaging probes</p><p>An imaging probe containing an indocyanine green detectable element and a QC-1 quencher was synthesized as illustrated in the following scheme.</p><p><img file="JP7720102B2_D0043.tif" /><img file="JP7720102B2_D0044.tif" /> Here, the Boc-protected peptide used in the second step was prepared as described above. The products of the coupling reaction with QC-1 and ICG were confirmed by liquid chromatography-mass spectrometry (LCMS).</p><p>A probe containing an ICG fluorophore and a QC-1 quencher (BMV109-ICG) was compared to a probe containing a Dylight780 fluorophore and a QC-1 quencher (BMV109-Dylight780) in in vivo and ex vivo studies. As shown in Figures 6A and 6B, the ICG-labeled probe exhibited improved tumor uptake and lower background signal compared to the Dylight780-labeled probe (see especially the 50 nmol dose in Figure 6B).</p><p><img file="JP7720102B2_D0045.tif" /></p><p>All patents, patent publications, and other publications mentioned herein are incorporated by reference in their entirety, as if each was individually and specifically incorporated by reference herein.</p><p>While specific examples have been provided, the above description is illustrative and not limiting. Any one or more of the features of the above-described embodiments can be combined in any manner with one or more features of any other embodiment of the present invention. Moreover, many modifications of the present invention will become apparent to those skilled in the art upon review of this specification. Therefore, the scope of the present invention should be determined by reference to the appended claims, along with their full range of equivalents.</p>